Myriad Genetics/$MYGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Myriad Genetics
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
Ticker
$MYGN
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
2,700
ISIN
US62855J1043
Website
Myriad Genetics Metrics
BasicAdvanced
$484M
-
-$1.12
2.02
-
Price and volume
Market cap
$484M
Beta
2.02
52-week high
$29.08
52-week low
$3.81
Average daily volume
2.1M
Financial strength
Current ratio
1.901
Quick ratio
1.404
Long term debt to equity
20.811
Total debt to equity
22.358
Interest coverage (TTM)
-28.74%
Profitability
EBITDA (TTM)
-29.4
Gross margin (TTM)
70.01%
Net profit margin (TTM)
-12.20%
Operating margin (TTM)
-10.72%
Effective tax rate (TTM)
20.16%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
-5.26%
Return on equity (TTM)
-13.84%
Valuation
Price to revenue (TTM)
0.575
Price to book
0.69
Price to tangible book (TTM)
3
Price to free cash flow (TTM)
-13.341
Free cash flow yield (TTM)
-7.50%
Free cash flow per share (TTM)
-39.35%
Growth
Revenue change (TTM)
7.38%
Earnings per share change (TTM)
-59.54%
3-year revenue growth (CAGR)
6.80%
3-year earnings per share growth (CAGR)
117.43%
What the Analysts think about Myriad Genetics
Analyst ratings (Buy, Hold, Sell) for Myriad Genetics stock.
Bulls say / Bears say
Myriad Genetics has reaffirmed its commitment to a transformation strategy aimed at capitalizing on underutilized market segments, with a revised revenue growth target exceeding $1 billion by 2026. (markets.businessinsider.com)
The company is progressing toward the commercial launch of its first AI-driven prostate cancer test, in partnership with PATHOMIQ, by the end of 2025, potentially opening new revenue streams. (thestockcatalyst.com)
Analysts have set 12-month price targets for Myriad Genetics, with an average target of $14.36, indicating potential upside from current levels. (nasdaq.com)
Bank of America has lowered its price target for Myriad Genetics to $11.00, maintaining an underperform rating, reflecting concerns about the company's future performance. (americanbankingnews.com)
The company reported a net cash outflow from operating activities of $16.3 million in the first quarter of 2025, indicating potential liquidity challenges. (finviz.com)
Myriad Genetics has lowered its 2025 revenue guidance to a range of $807-$823 million, down from the previous $840-$860 million, citing challenges in its pharmacogenomics and women's health businesses. (finviz.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
Myriad Genetics Financial Performance
Revenues and expenses
Myriad Genetics Earnings Performance
Company profitability
Myriad Genetics News
AllArticlesVideos
INVESTOR ALERT: Investigation of Myriad Genetics, Inc. (MYGN) Announced by Holzer & Holzer, LLC
GlobeNewsWire·5 days ago
Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen
GlobeNewsWire·4 weeks ago
Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Myriad Genetics stock?
Myriad Genetics (MYGN) has a market cap of $484M as of June 30, 2025.
What is the P/E ratio for Myriad Genetics stock?
The price to earnings (P/E) ratio for Myriad Genetics (MYGN) stock is 0 as of June 30, 2025.
Does Myriad Genetics stock pay dividends?
No, Myriad Genetics (MYGN) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Myriad Genetics dividend payment date?
Myriad Genetics (MYGN) stock does not pay dividends to its shareholders.
What is the beta indicator for Myriad Genetics?
Myriad Genetics (MYGN) has a beta rating of 2.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.